RGEN
REPLIGEN CORPPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 21 ▼ 1 insider sell $536.5K at $140.00
- Jun 25 ▼ 1 insider sell $106.3K at $145.00
- Jun 30 ▲ 4 funds open new positions (13F)
- Jul 7 ▲ Benchmark upgrades
- Jul 16 ▼ 1 insider sell $79.5K at $150.00
- Aug 20 ▼ 1 insider sell $976.7K at $180.00
- Sep 4 ▼ 1 insider sell $503.5K at $165.90
- Sep 21 to Sep 24 ▼ 2 days of insider sells: $3.4M by 1 insider, avg $187.05
- Oct 5 ▼ 1 insider sell $1.0M at $187.29
- Oct 27 ▲ Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY as reported…
- Oct 27 ▲ Earnings: RGEN Q3 2026 Earnings: EPS $0.53 (+12.8% vs est)
- Oct 27 ▲ Repligen reported Q3 2026 adjusted EPS of $0.53, beating the $0.46 c…
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $6.7M.
- InstitutionsBULLISH
Q2 2026: 37 added (4 new), 23 trimmed or exited. Largest new: William Blair Investment Management $107.6M, Marshall Wace $38.5M.
- AnalystsBULLISH
22 of 27 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.581 → $0.524 over 90 days. 0 up, 12 down in 30 days.
- Short sellersSTEADY
Short interest −1.3% to 7.05M shares. 4.9 days to cover, ≈11.0% of shares.
- TrendDOWNTREND
8% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MAVERICK CAPITAL LTD | ADD | $270.8M |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | $239.1M |
| WASATCH ADVISORS LP | ADD | $217.0M |
| AMERIPRISE FINANCIAL INC | ADD | $215.0M |
| Holocene Advisors, LP | ADD | $176.3M |
| CONGRESS ASSET MANAGEMENT CO | ADD | $138.1M |
| GOLDMAN SACHS GROUP INC | ADD | $131.7M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | NEW | $107.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analystsPrice is below the lowest target. Median implies +23%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 28, 2026 | RBC Capital MAINTAIN | Outperform |
| Oct 19, 2026 | Canaccord Genuity MAINTAIN | Hold |
| Oct 7, 2026 | Barclays MAINTAIN | Overweight |
| Sep 9, 2026 | UBS MAINTAIN | Buy |
| Jul 30, 2026 | Wells Fargo MAINTAIN | Overweight |
| Jul 29, 2026 | JP Morgan MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Douglass Brian Robb CHIEF PRODUCT OFFICER Oct 6, 2026 | AWARD | 675 sh |
Douglass Brian Robb CHIEF PRODUCT OFFICER Oct 6, 2026 | AWARD | 700 sh |
Loeillot Olivier Chief Executive Officer Oct 5, 2026 | EXERCISE | $651.1K |
Loeillot Olivier Chief Executive Officer Oct 5, 2026 | SELL | $238.3K |
Loeillot Olivier Chief Executive Officer Oct 5, 2026 | SELL | $798.4K |
Loeillot Olivier Chief Executive Officer Oct 2, 2026 | TAX W/H | $226.8K |
Garland Jason K CFO Sep 25, 2026 | TAX W/H | $79.9K |
Loeillot Olivier Chief Executive Officer Sep 24, 2026 | EXERCISE | $705.7K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.52 | $0.50–$0.55 | -9.9% | $241.1M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 2 press releases · 8 bullish · 0 bearish · 1 mixed · 5 neutral- NEUTRAL 8-KNov 6, 2026
Repligen issued $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due…
The refinancing extends debt maturities and lowers interest costs while adding cash. Monitor the company's use of the $458.6M cash proceeds and any future conversion activity that could dilute…
- NEUTRAL 8-KOct 30, 2026
Repligen entered into privately negotiated exchange and subscription agreements to issue $1.0…
Monitor the closing of the transaction on November 6, 2026, and any subsequent share repurchase activity. The reduced interest expense and extended maturity profile are credit-positive, but the…
- BULLISH 8-KOct 27, 2026
Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY as reported and 12.5% organic, beating…
The raised guidance and strong organic growth signal sustained end-market recovery and successful integration of BioLife. Watch for Q4 revenue trajectory and margin expansion from BioLife synergies…
- BULLISH PRESS-RELEASEOct 27, 2026
Repligen reported Q3 2026 adjusted EPS of $0.53, beating the $0.46 consensus by 15.2%, and revenue…
The raised guidance and strong organic growth signal improving end-market demand. Monitor Q4 for BioLife revenue contribution and margin accretion, as integration synergies are expected to enhance…
All RGEN filing & press-release reports (16)
- 8-K reportNov 6, 2026
- 8-K reportOct 30, 2026
- 8-K reportOct 27, 2026
- PRESS-RELEASE reportOct 27, 2026
- INST-CLUSTER reportOct 15, 2026
- SC 13G/A reportOct 7, 2026
- 8-K reportOct 6, 2026
- PRESS-RELEASE reportOct 6, 2026
- S-4 reportAug 24, 2026
- 8-K reportJul 28, 2026
- 425, 8-K reportJul 22, 2026
- PRESS-RELEASE reportJul 22, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 5, 2026
- PRESS-RELEASE reportApr 22, 2026